These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. PTOV1 expression predicts prostate cancer in men with isolated high-grade prostatic intraepithelial neoplasia in needle biopsy. Morote J; Fernández S; Alaña L; Iglesias C; Planas J; Reventós J; Ramón Y Cajal S; Paciucci R; de Torres IM Clin Cancer Res; 2008 May; 14(9):2617-22. PubMed ID: 18451224 [TBL] [Abstract][Full Text] [Related]
25. Levels of expression of p27KIP1 protein in human prostate and prostate cancer: an immunohistochemical analysis. Erdamar S; Yang G; Harper JW; Lu X; Kattan MW; Thompson TC; Wheeler TM Mod Pathol; 1999 Aug; 12(8):751-5. PubMed ID: 10463475 [TBL] [Abstract][Full Text] [Related]
26. The role of the androgen receptor in the development and progression of prostate cancer. Jenster G Semin Oncol; 1999 Aug; 26(4):407-21. PubMed ID: 10482183 [TBL] [Abstract][Full Text] [Related]
27. Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with gleason score and chromosome 8p deletion. Bethel CR; Faith D; Li X; Guan B; Hicks JL; Lan F; Jenkins RB; Bieberich CJ; De Marzo AM Cancer Res; 2006 Nov; 66(22):10683-90. PubMed ID: 17108105 [TBL] [Abstract][Full Text] [Related]
28. Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression. Baretton GB; Klenk U; Diebold J; Schmeller N; Löhrs U Br J Cancer; 1999 May; 80(3-4):546-55. PubMed ID: 10408865 [TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical expression of hepatocyte growth factor and c-Met/HGF receptor in benign and malignant human prostate tissue. Nakashiro K; Hayashi Y; Oyasu R Oncol Rep; 2003; 10(5):1149-53. PubMed ID: 12883672 [TBL] [Abstract][Full Text] [Related]
30. Low stroma androgen receptor level in normal and tumor prostate tissue is related to poor outcome in prostate cancer patients. Wikström P; Marusic J; Stattin P; Bergh A Prostate; 2009 Jun; 69(8):799-809. PubMed ID: 19189305 [TBL] [Abstract][Full Text] [Related]
32. Reduction of QM protein expression correlates with tumor grade in prostatic adenocarcinoma. Altinok G; Powell IJ; Che M; Hormont K; Sarkar FH; Sakr WA; Grignon D; Liao DJ Prostate Cancer Prostatic Dis; 2006; 9(1):77-82. PubMed ID: 16331298 [TBL] [Abstract][Full Text] [Related]
33. Detection of discrete androgen receptor epitopes in prostate cancer by immunostaining: measurement by color video image analysis. Tilley WD; Lim-Tio SS; Horsfall DJ; Aspinall JO; Marshall VR; Skinner JM Cancer Res; 1994 Aug; 54(15):4096-102. PubMed ID: 7518349 [TBL] [Abstract][Full Text] [Related]
34. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells. Fujimoto N; Miyamoto H; Mizokami A; Harada S; Nomura M; Ueta Y; Sasaguri T; Matsumoto T Cancer Invest; 2007 Feb; 25(1):32-7. PubMed ID: 17364555 [TBL] [Abstract][Full Text] [Related]
35. Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations. Shi Y; Chatterjee SJ; Brands FH; Shi SR; Pootrakul L; Taylor CR; Datar R; Cote RJ BJU Int; 2006 Jan; 97(1):170-8. PubMed ID: 16336351 [TBL] [Abstract][Full Text] [Related]
36. Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery. Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Cheng L; Bostwick DG J Urol; 1999 Apr; 161(4):1233-7. PubMed ID: 10081876 [TBL] [Abstract][Full Text] [Related]
37. GnRH receptor and androgen receptor status and outcome of advanced prostate carcinomas. Szabó J; Bartók K; Krenács T; Szepesváry Z; Szende B Anticancer Res; 2009 Feb; 29(2):681-4. PubMed ID: 19331222 [TBL] [Abstract][Full Text] [Related]
38. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Kahl P; Gullotti L; Heukamp LC; Wolf S; Friedrichs N; Vorreuther R; Solleder G; Bastian PJ; Ellinger J; Metzger E; Schüle R; Buettner R Cancer Res; 2006 Dec; 66(23):11341-7. PubMed ID: 17145880 [TBL] [Abstract][Full Text] [Related]
39. Expression of the forkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the androgen receptor in prostate cancer but is not directly regulated by androgens or hypoxia. Banham AH; Boddy J; Launchbury R; Han C; Turley H; Malone PR; Harris AL; Fox SB Prostate; 2007 Jul; 67(10):1091-8. PubMed ID: 17477366 [TBL] [Abstract][Full Text] [Related]
40. Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer. Henshall SM; Quinn DI; Lee CS; Head DR; Golovsky D; Brenner PC; Delprado W; Stricker PD; Grygiel JJ; Sutherland RL Cancer Res; 2001 Jan; 61(2):423-7. PubMed ID: 11212224 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]